Brevan Howard Capital Management LP
Position in KALV — KalVista Pharmaceuticals, Inc.
CIK 1512857
ST. HELIER, Y9
Position in KALV
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,517,236
+$1,562,012 QoQ
Shares Held
125,049
+111.4% QoQ
Ownership
0.235%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#61
of 182 holders
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in KALV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Brevan Howard Capital Management LP holds $135,514,277 across 173 Biotechnology names. KALV ranks #14 (1.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BBIO |
BridgeBio Pharma, Inc.
|
81,570 | $6,057,388 | |
| 2 | ASND |
Ascendis Pharma A/S
|
26,200 | $5,992,726 | |
| 3 | SNDX |
Syndax Pharmaceuticals Inc
|
204,845 | $4,785,179 | |
| 4 | TERN |
Terns Pharmaceuticals, Inc.
|
88,596 | $4,670,780 | |
| 5 | MRNA |
Moderna, Inc.
|
89,594 | $4,551,375 | |
| 6 | SLNO |
Soleno Therapeutics Inc
|
135,621 | $4,540,590 | |
| 7 | RARE |
Ultragenyx Pharmaceutical Inc.
|
215,845 | $4,521,951 | |
| 8 | INCY |
Incyte Corp
|
46,448 | $4,371,685 |
All Filings in KALV
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,517,236 | 125,049 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $955,224 | 59,147 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $680,594 | 55,878 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $150,729 | 13,333 | Shares | Defined | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||